PCSK9 is a serine protease that primarily binds to the low-density lipoprotein receptor (LDLR) on the cell membrane in the plasma, leading to the internalization of LDLR and subsequent vesicular ...

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

AZD0780 inhibits the lysosomal trafficking of PCSK9-LDLR complexes, preventing PCSK9-induced LDLR degradation. Dr Michael J Koren, CEO and medical director of the Jacksonville Center for Clinical ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard statin therapy, the pill reduced low-density lipoprotein cholesterol ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

Enzyme-linked immunosorbent assays were used to compare serum concentrations of TMAO, apolipoprotein A4 (APOA4), and proprotein convertase subtilisin/kexin type 9 (PCSK9) between patients with ...